EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

The Sulfatase Pathway for Estrogen Formation: Targets for the Treatment and Diagnosis of Hormone-Associated Tumors

Lena Secky, Martin Svoboda, Lukas Klameth, Erika Bajna, Gerhard Hamilton, Robert Zeillinger, Walter Jäger, Theresia Thalhammer

Journal of Drug Delivery · 13.02.2013 · 2013 · 1-13

DOI: 10.1155/2013/957605 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Drug Delivery, erschienen am 13.02.2013. Verfasst von Lena Secky und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer…. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: FP-6 STREP.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The extragonadal synthesis of biological active steroid hormones from their inactive precursors in target tissues is named “intracrinology.” Of particular importance for the progression of estrogen-dependent cancers is the in situ formation of the biological most active estrogen, 17beta-estradiol (E2). In cancer cells, conversion of inactive steroid hormone precursors to E2 is accomplished from inactive, sulfated estrogens in the “sulfatase pathway” and from androgens in the “aromatase pathway.” Here, we provide an overview about expression and function of enzymes of the “sulfatase pathway,” particularly steroid sulfatase (STS) that activates estrogens and estrogen sulfotransferase (SULT1E1) that converts active estrone (E1) and other estrogens to their inactive sulfates. High expression of STS and low expression of SULT1E1 will increase levels of active estrogens in malignant tumor cells leading to the stimulation of cell proliferation and cancer progression. Therefore, blocking the “sulfatase pathway” by STS inhibitors may offer an attractive strategy to reduce levels of active estrogens. STS inhibitors either applied in combination with aromatase inhibitors or as novel, dual aromatase-steroid sulfatase inhibiting drugs are currently under investigation. Furthermore, STS inhibitors are also suitable as enzyme–based cancer imaging agents applied in the biomedical imaging technique positron emission tomography (PET) for cancer diagnosis.

Autor:innen und Institutionen

  • Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Förderung

  • FP-6 STREP

Zitieren

APA

Secky, L., Svoboda, M., Klameth, L., Bajna, E., Hamilton, G., Zeillinger, R., Jäger, W., & Thalhammer, T. (2013). The Sulfatase Pathway for Estrogen Formation: Targets for the Treatment and Diagnosis of Hormone-Associated Tumors. Journal of Drug Delivery, 2013, 1-13. https://doi.org/10.1155/2013/957605

Vancouver

Secky L, Svoboda M, Klameth L, Bajna E, Hamilton G, Zeillinger R, et al. The Sulfatase Pathway for Estrogen Formation: Targets for the Treatment and Diagnosis of Hormone-Associated Tumors. Journal of Drug Delivery. 2013;2013:1-13. doi:10.1155/2013/957605

BibTeX
@article{Secky2013,
  author = {Secky, Lena and Svoboda, Martin and Klameth, Lukas and Bajna, Erika and Hamilton, Gerhard and Zeillinger, Robert and Jäger, Walter and Thalhammer, Theresia},
  title = {The Sulfatase Pathway for Estrogen Formation: Targets for the Treatment and Diagnosis of Hormone-Associated Tumors},
  journal = {Journal of Drug Delivery},
  year = {2013},
  volume = {2013},
  pages = {1--13},
  doi = {10.1155/2013/957605}
}
Kostenlos starten →